Newsletter Subject

The #1 Biotech Stock to Own Today

From

marketsflix.com

Email Address

mf@marketsflix.com

Sent On

Sat, Jan 23, 2021 12:00 AM

Email Preheader Text

It's not just about money anymore - it's about which country is going to lead in the future of medic

It's not just about money anymore - it's about which country is going to lead in the future of medicine for the next 50 years.  Dear Fellow Skeptic, On November 16, 2016, CBS News [shocked the medical world]( when they reported on a tiny biotech that restored blindness in mice. The breakthrough was the first to reveal a revolutionary new treatment that could simply replace sick genes with healthy ones. Scientists called it "the most consequential discovery in medicine." They said it was "giving them power they could only imagine before." That's because this new breakthrough can treat all 6,000 genetic diseases. But scientists aren't the only ones who see its true potential - As the true power of this treatment comes into focus, it's become a national security issue for us and our NATO allies. And that's what makes this breakthrough so unique: It's not just about money anymore -[it's about which country is going to lead in the future of medicine for the next 50 years.]( That's the real reason President Trump signed "Executive Order 13771" just 10 days after taking office... ...for us to win the battle for the future, Trump had to reduce regulations at the FDA first. This treatment will not just change medicine - it has the potential to eliminate genetic disease for our species. And because of that, [it's going to create more millionaires than any other single breakthrough in history](. More than 5G, more than cannabis and more than the internet. There's a tiny biotech that won the patent on this breakthrough. The current market capitalization is just $1.5 billion. But analysts like Keith S. experts expect it to soar to what Facebook is worth, or $1 Trillion, by 2021. That's because Wall Street sees the potential of Amgen. Early investors in Amgen, one of the pioneers of biological medicine, earned as much as 46,751% on their money.  [Our research proves that anyone who gets in today could turn every $1,000 into $1.57 million (or more)!]( That's if the company doesn't get taken over for fast 300% gains first. [CLICK HERE to see how you can profit from this rare opportunity](  "The Buck Stops Here" [Click Here]( Dylan Chairman, Behind the Markets If you are you having trouble receiving your Markets Flix subscription, you can ensure its arrival in your mailbox by [whitelisting Markets Flix and mf@marketsflix.com.]( Markets Flix (collectively, the “Company” or “we” used herein) bears no responsibility or control over the content of the advertisement and/or the product or service offered. This email is a paid advertisement. It is for a product or service that is not offered, recommended or endorsed by Markets Flix and neither the company nor its affiliates bear responsibility or control over the content of the advertisement and the product or service offered. There is a very high degree of risk involved in trading. Past results are not indicative of future returns. Markets Flix, all individuals and companies affiliated with this site assume no responsibilities for your trading and investment results. The indicators, strategies, columns, articles and all other features are for educational purposes only and should not be construed as advice. Information for any trading observations are obtained from sources believed to be reliable, but we do not warrant its completeness or accuracy, or warrant any results from the use of the information. Your use of the trading observations is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness of the information. By reading, downloading or otherwise consuming this content your information may be shared with our educational partners. You must assess the risk of any trade with your broker and make your own independent decisions regarding any securities mentioned herein. Affiliates of Markets Flix may have a position or effect transactions in the securities described herein (or options thereon) and/or otherwise employ trading strategies that may be consistent or inconsistent with the provided strategies.  Your subscriber Id is: 39357a76f6d08b16239fd2ffa65e9c6f Proudly brought to you by: Markets Flix of 3rd Fl, N&S Tower, 4 Selsdon Way, London, E14 9GL, UK In order to unsubscribe from this mailing list, please click [here](

Marketing emails from marketsflix.com

View More
Sent On

04/02/2021

Sent On

03/02/2021

Sent On

03/02/2021

Sent On

02/02/2021

Sent On

01/02/2021

Sent On

01/02/2021

Email Content Statistics

Subscribe Now

Subject Line Length

Data shows that subject lines with 6 to 10 words generated 21 percent higher open rate.

Subscribe Now

Average in this category

Subscribe Now

Number of Words

The more words in the content, the more time the user will need to spend reading. Get straight to the point with catchy short phrases and interesting photos and graphics.

Subscribe Now

Average in this category

Subscribe Now

Number of Images

More images or large images might cause the email to load slower. Aim for a balance of words and images.

Subscribe Now

Average in this category

Subscribe Now

Time to Read

Longer reading time requires more attention and patience from users. Aim for short phrases and catchy keywords.

Subscribe Now

Average in this category

Subscribe Now

Predicted open rate

Subscribe Now

Spam Score

Spam score is determined by a large number of checks performed on the content of the email. For the best delivery results, it is advised to lower your spam score as much as possible.

Subscribe Now

Flesch reading score

Flesch reading score measures how complex a text is. The lower the score, the more difficult the text is to read. The Flesch readability score uses the average length of your sentences (measured by the number of words) and the average number of syllables per word in an equation to calculate the reading ease. Text with a very high Flesch reading ease score (about 100) is straightforward and easy to read, with short sentences and no words of more than two syllables. Usually, a reading ease score of 60-70 is considered acceptable/normal for web copy.

Subscribe Now

Technologies

What powers this email? Every email we receive is parsed to determine the sending ESP and any additional email technologies used.

Subscribe Now

Email Size (not include images)

Font Used

No. Font Name
Subscribe Now

Copyright © 2019–2024 SimilarMail.